Maravai LifeSciences Holdings Inc. Class A Common Stock vs Williams-Sonoma, Inc. — how do they compare? Maravai LifeSciences Holdings Inc. Class A Common Stock trades at $6.56 (market cap $972.90M), while Williams-Sonoma, Inc. trades at $243.14 (market cap $28.26B). The key difference: Williams-Sonoma, Inc. is far larger — about 29× Maravai LifeSciences Holdings Inc. Class A Common Stock's market cap, and Williams-Sonoma, Inc. pays a 1.27% dividend while Maravai LifeSciences Holdings Inc. Class A Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Maravai LifeSciences Holdings Inc. Class A Common Stock for 0 Days and Williams-Sonoma, Inc. for 59 Days on average.
| MRVI | WSM | |
|---|---|---|
Market Cap | $972.90M | $28.26B |
Volume | 4,325,710 | 1,108,410 |
Sector | Health | Consumer Cyclical |
52-Week High | $9.00 | $251.81 |
52-Week Low | $2.83 | $168.64 |
Typical Hold Time | 0 Days | 59 Days |
Enterprise Value | $1.08B | $28.76B |
Dividend Yield | — | 1.27% |
Signals from Pluang's Aura AI — not financial advice
Maravai LifeSciences (MRVI) trades at $6.53, down 7.51% in the last session amid mixed signals. The stock shows improving fundamentals with Q2 2026 revenue growth of 9% and three consecutive earnings beats, though it remains unprofitable with a -37.07% net margin. Technical analysis indicates neutral positioning with key support at $6 and resistance at $7. Recent news highlights patent expansions in China and institutional accumulation.
The outlook remains cautiously optimistic with analyst consensus pointing to 7% upside potential to the $7.00 price target. Key opportunities include margin expansion and RNA technology leadership, while risks center on persistent cash burn and competitive pressures in life sciences. The stock offers speculative growth potential for risk-tolerant investors.
Williams-Sonoma (WSM) trades at $242.48, up 1.52% recently, with a bullish technical outlook and strong fundamentals. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results pending. Profitability remains robust, with a net income margin of 14.73% and ROE of 54.96%, while valuation ratios like P/E of 24.61 and P/S of 3.62 reflect market confidence. Recent news highlights growth through minimal discounting and AI integration, supporting positive sentiment.
The outlook for WSM is favorable, driven by earnings momentum and market share gains, but risks include housing market sensitivity and competitive pressures. Analyst consensus leans hold with a $246.31 price target, suggesting modest upside. Institutional interest is steady, though insider selling warrants monitoring. Overall, the stock presents a balanced opportunity with growth potential tempered by sector-specific headwinds.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Maravai LifeSciences Holdings Inc. is a life sciences company supporting drug therapy, diagnostic, and vaccine development through four operating brands: TriLink BioTechnologies (nucleic acid and mRNA synthesis), Cygnus Technologies (biologics safety testing), Glen Research (oligonucleotide synthesis materials), and Alphazyme (enzyme manufacturing). It serves biotech and biopharma customers from discovery through commercial manufacturing.
Read more on MRVI →With a wide retail and direct-to-consumer presence, Williams-Sonoma is a leader in the $300 billion domestic home category, focused on expanding its exposure in the B2B, marketplace, and franchise areas. Namesake Williams-Sonoma (175 stores) offers high-end cooking essentials, while Pottery Barn (189) provides casual home accessories. Brand extensions include Pottery Barn Kids (52) and PBteen. West Elm (121) is an emerging concept for young professionals, and Rejuvenation (9) offers lighting and house parts. Williams-Sonoma also has a business-to-business team that supports projects that range from residential to large-scale commercial.
Read more on WSM →